Research programme: sphingosine 1 phosphate receptor antagonists - NOXXON

Drug Profile

Research programme: sphingosine 1 phosphate receptor antagonists - NOXXON

Alternative Names: NOX S-91; NOX S-93

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator NOXXON Pharma AG
  • Class Nucleotide aptamers; Oligonucleotides
  • Mechanism of Action Angiogenesis inhibitors; Sphingosine-1-phosphate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer; Eye disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in Germany
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Germany
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top